Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech Inc. has demonstrated a positive trajectory through the promising data released from multiple Phase 2 studies, particularly highlighting the effectiveness of its leading product, Ampligen, in treating post-COVID conditions and colorectal cancer. The company’s strategic focus on pancreatic cancer and the successful outcomes of prior studies suggest significant potential for future advancements, which could serve as key catalysts for stock performance. Overall, AIM ImmunoTech's valuation reflects a strategic balance of inherent risks against the substantial growth prospects and substantial upside opportunities presented by their innovative therapeutics.

Bears say

AIM ImmunoTech Inc experienced significant net losses, reporting a loss of $3.3 million or an EPS of $(1.57) in comparison to consensus estimates, signaling operational challenges and financial instability. The company’s prior quarterly figures reflected a net loss of $4.2 million with an EPS of $(1.39), again falling short of expectations, which raises concerns about its profitability and financial health. Additionally, several key risks threaten the company's outlook, including balance sheet liquidity issues, the potential failure of product candidates in clinical trials, challenges in obtaining regulatory approvals, and difficulties in commercialization and reimbursement, all exacerbated by competitive and macroeconomic pressures.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.